0
0
Biontech and Pfizer have begun their first clinical trial to evaluate a Corona vaccine specifically tailored to the Omicron variant. The study will evaluate the safety, tolerability and efficacy of the vaccine candidate, the two companies announced today. The study is expected to enroll up to 1,420 subjects, who will be divided into three groups.
The first group includes just over 600 people who have already received two doses of the previous vaccine between 90 and 180 days before the start of the study and will now receive one or two doses of the Omicron vaccine. The second group, almost as large, consists of boosted people who will receive another dose of the conventional vaccine or one dose of the Omicron vaccine. The third group, with just over 200 subjects, is made up of unvaccinated people who have not previously had Covid-19 and will then receive three doses of the Omicron vaccine.
“The study is part of our scientific approach to developing a variant-based vaccine that provides protection from Omicron similar to what we have observed with previous variants, while lasting longer,” explained Biontech CEO Ugur Sahin. Vaccines still offer a high level of protection against severe courses of Omicron, he added.
- source: derstandard.at/picture: Pfizer Inc. (@pfizer) / Twitter
This post has already been read 471 times!
